Department of Urology, Korea University College of Medicine, Seoul 136-705, Republic of Korea.
Asian J Androl. 2012 Sep;14(5):752-7. doi: 10.1038/aja.2012.68. Epub 2012 Aug 6.
MicroRNAs (miRs) are small noncoding RNAs that have been reported to be promising diagnostic tools. We used quantitative real-time reverse transcription PCR (RT-qPCR) to analyze differentially expressed miRNAs in prostate tumor samples to determine its prognostic value. From 2007 to 2009, tumor tissues were obtained from 73 radical prostatectomy specimens. Differentially expressed miR-96, -145 and -221 were validated by TaqMan RT-qPCR using all 73 tissues. The prognostic value was assessed in terms of biochemical recurrence using Kaplan-Meier and Cox regression analyses. For our patient cohort, the mean age was 64.7 years (50-76 years) and the mean prostate-specific antigen (PSA) was 7.5 ng ml(-1). During the follow-up period (mean, 19.4 months), 14 of 73 (19.2%) patients developed biochemical recurrence. Expression of miR-96, -145 and -221 correlated strongly with each other, but there were no correlations between miRNA expression and clinicopathologic parameters. Kaplan-Meier survival curves using the log-rank test showed a decreased biochemical recurrence-free interval with pathologic stage (P<0.001). In addition, patients with Gleason scores over 8, compared with those with a Gleason score of 6, showed a decreased biochemical recurrence-free interval in Kaplan-Meier analysis (P=0.001). However, expression of miR-96, -145 and -221 did not correlate with the biochemical recurrence interval in Kaplan-Meier survival curves or by multivariate analysis using the Cox proportional hazard regression model, either. In conclusion, we did not observe a significant correlation between the expression of miR-96, -145 and -221 and clinicopathologic parameters. To utilize miRNA as a diagnostic tool in clinical practice, more research is needed to understand miRNA mechanisms, identify miRNA targets, and further characterize miRNA function.
微小 RNA（miRs）是小的非编码 RNA，已被报道为有前途的诊断工具。我们使用定量实时逆转录 PCR（RT-qPCR）分析前列腺肿瘤样本中差异表达的 miRNAs，以确定其预后价值。 2007 年至 2009 年，从 73 例根治性前列腺切除术标本中获得肿瘤组织。使用所有 73 个组织通过 TaqMan RT-qPCR 验证差异表达的 miR-96、-145 和-221。使用 Kaplan-Meier 和 Cox 回归分析评估生化复发的预后价值。对于我们的患者队列，平均年龄为 64.7 岁（50-76 岁），平均前列腺特异性抗原（PSA）为 7.5ngml（-1）。在随访期间（平均 19.4 个月），73 例患者中有 14 例（19.2%）发生生化复发。 miR-96、-145 和-221 的表达彼此之间强烈相关，但 miRNA 表达与临床病理参数之间没有相关性。使用对数秩检验的 Kaplan-Meier 生存曲线显示，生化无复发生存间隔与病理分期呈负相关（P<0.001）。此外，与 Gleason 评分 6 相比，Gleason 评分超过 8 的患者在 Kaplan-Meier 分析中显示生化无复发生存间隔缩短（P=0.001）。然而，miR-96、-145 和-221 的表达与 Kaplan-Meier 生存曲线或 Cox 比例风险回归模型的多变量分析中的生化复发间隔均无相关性。总之，我们没有观察到 miR-96、-145 和-221 的表达与临床病理参数之间存在显著相关性。为了在临床实践中利用 miRNA 作为诊断工具，需要进一步研究以了解 miRNA 机制，鉴定 miRNA 靶标，并进一步表征 miRNA 功能。
